Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents with Chronic HCV: Part 1 of the DORA Study
(2020) Hepatology — Vol. 71, n° 2, p. 456-462 (2020)
Files
DORA-part2-AASLD-Final-draft-post-approvalchanges-SS-5-28-19-SS.pdf
Open Access - Adobe PDF
- 299.16 KB
Details
- Authors
- Abstract
- The pangenotypic regimen of glecaprevir and pibrentasvir (G/P) is approved to treat adults with chronic hepatitis C virus (HCV) infection, and has yielded high cure rates in adults in clinical trials. Approved treatment options for pediatrics may include ribavirin (RBV). A pangenotypic regimen for pediatric patients remains an unmet need. DORA is an ongoing phase 2/3, non-randomized, open-label study evaluating the pharmacokinetics (PK), safety, and efficacy of G/P in pediatric patients with chronic HCV. This analysis includes Part 1 of the study, conducted in adolescent patients 12-17 years old given the adult regimen of G/P (300 mg/120 mg) once-daily for 8-16 weeks according to the indication durations used in adults. Patients were either treatment-naïve or experienced with interferon (IFN)- based regimens. The primary PK endpoint was steady-state exposures for glecaprevir and pibrentasvir; the primary efficacy endpoint was sustained virologic response 12 weeks post-treatment (SVR12). The secondary efficacy endpoints were on-treatment virologic failure, relapse, and reinfection. Safety and tolerability were monitored. Part 1 enrolled 48 adolescent patients infected with genotypes 1, 2, 3, or 4; 47 of whom were administered G/P. All 47 patients (100%) achieved SVR12. No on-treatment virologic failures or relapses occurred. PK exposures of glecaprevir and pibrentasvir were comparable to exposures in adults. No AEs led to treatment discontinuation, and no serious AEs occurred. CONCLUSION: Adolescent patients with chronic HCV infection treated with G/P achieved a comparable exposure to adults, 100% SVR12 rate, and safety profile consistent with that in adults. This is the first pangenotypic regimen to demonstrate 100% efficacy within the adolescent population in as little as 8 weeks of treatment.
- Affiliations
Citations
Jonas, M. M., Squires, R. H., Rhee, S. M., Lin, C.-W., Bessho, K., Feiterna-Sperling, C., Hierro, L., Kelly, D., Ling, S. C., Strokova, T., del Valle-Segarra, A., Lovell, S., Liu, W., Ng, T. I., Porcalla, A., Gonzalez, Y. S., Burroughs, M., & Sokal, E. (2020). Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents with Chronic HCV: Part 1 of the DORA Study. Hepatology, 71(2), 456-462. https://doi.org/10.1002/hep.30840 (Original work published 2020)